Document Detail

Levosimendan improves postresuscitation myocardial dysfunction after beta-adrenergic blockade.
MedLine Citation:
PMID:  16131457     Owner:  NLM     Status:  MEDLINE    
In earlier studies, we found that a nonselective beta-adrenergic blocking agent, propranolol, facilitated cardiac resuscitation, reduced postresuscitation myocardial ectopy, and improved postresuscitation survival. However, the potential adverse effects and specifically the negative inotropic actions of propranolol prompted our further investigation of the potential value of a non-beta-adrenergic inotropic drug, levosimendan, in conjunction with propranolol, for minimizing postresuscitation myocardial dysfunction after successful resuscitation from cardiac arrest. Ventricular fibrillation was induced and untreated for 7 minutes in 15 domestic pigs, which were divided into propranolol, propranolol plus levosimendan, and control groups. Propranolol was administered as a bolus dose of 0.1 mg/kg during cardiac arrest. Electrical defibrillation was attempted after 12 minutes of cardiac arrest including 5 minutes of precordial compression. Levosimendan was administered at 10 minutes after successful resuscitation in a dose of 20 microg/kg and followed by infusion of 0.4 microg/kg/min over the ensuing 220 minutes. Propranolol reduced energies or numbers of defibrillatory shocks and postresuscitation myocardial ectopy, and it improved postresuscitation myocardial dysfunction. When levosimendan was added, postresuscitation myocardial contractile function was improved even more.
Jinglan Wang; Max Harry Weil; Wanchun Tang; Shijie Sun; Lei Huang
Related Documents :
1804827 - Lidocaine prophylaxis in acute myocardial infarction.
7302777 - Evaluation of lorcainide, a new anti-arrhythmic agent.
6148617 - Prevention of ventricular fibrillation during acute myocardial infarction by intravenou...
2426997 - Prophylactic lidocaine in the prehospital patient with chest pain of suspected cardiac ...
7426197 - Assessment of prognostic factors in patients undergoing surgery for non-rheumatic mitra...
6818687 - Cardiac catabolic factors: the degradation of heart valve intercellular matrix.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  The Journal of laboratory and clinical medicine     Volume:  146     ISSN:  0022-2143     ISO Abbreviation:  J. Lab. Clin. Med.     Publication Date:  2005 Sep 
Date Detail:
Created Date:  2005-08-31     Completed Date:  2005-09-26     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0375375     Medline TA:  J Lab Clin Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  179-83     Citation Subset:  AIM; IM    
Institute of Critical Care Medicine, 35100 Bob Hope Drive, Rancho Mirage, CA 92270, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / pharmacology*
Blood Pressure / drug effects*
Cardiopulmonary Resuscitation*
Cardiotonic Agents / pharmacology*
Drug Therapy, Combination
Heart Arrest / physiopathology
Heart Rate / drug effects*
Hydrazones / pharmacology*
Propranolol / pharmacology*
Pyridazines / pharmacology*
Grant Support
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Cardiotonic Agents; 0/Hydrazones; 0/Pyridazines; 131741-08-7/simendan; 525-66-6/Propranolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Nonparathyroid hormone-mediated calcium resorption in a rat model of immune glomerulonephritis.
Next Document:  A cross-talk between RNA splicing and signaling pathway alters Fas gene expression at post-transcrip...